To guard against possible problems with clinical development of the drug candidate acoziborole as a treatment for human African trypanosomiasis (HAT), commonly known as sleeping sickness, two back-up candidates from the same class have been identified as options for future development.

Extensive pharmacokinetic profiling of possible oxaborole compounds led to the selection of SCYX-1608210 and SCYX-1330682, which demonstrated cure in the Stage 2 mouse model for sleeping sickness. Given the current success of other projects for sleeping sickness, further development was put on hold in 2013 and will only recommence if needed.

Project updates


DNDi continues to provide support and advice to researchers working on discovery of new candidates for HAT and maintains two back-up candidates from the oxaborole class to ensure future development options, if needed.